62 related articles for article (PubMed ID: 2499164)
1. Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate.
Mallette LE; LeBlanc AD; Pool JL; Mechanick JI
J Bone Miner Res; 1989 Apr; 4(2):143-8. PubMed ID: 2499164
[TBL] [Abstract][Full Text] [Related]
2. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study.
Pacifici R; McMurtry C; Vered I; Rupich R; Avioli LV
J Clin Endocrinol Metab; 1988 Apr; 66(4):747-53. PubMed ID: 3126214
[TBL] [Abstract][Full Text] [Related]
3. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
[TBL] [Abstract][Full Text] [Related]
4. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
Sato S; Ohosone Y; Suwa A; Yasuoka H; Nojima T; Fujii T; Kuwana M; Nakamura K; Mimori T; Hirakata M
J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
[TBL] [Abstract][Full Text] [Related]
5. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
[TBL] [Abstract][Full Text] [Related]
6. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
Bolanca S; Korsić M; Dekanić D; Cvijetić S
Acta Med Croatica; 1998; 52(3):159-63. PubMed ID: 9818438
[TBL] [Abstract][Full Text] [Related]
7. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
[TBL] [Abstract][Full Text] [Related]
8. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
Sebaldt RJ; Ioannidis G; Adachi JD; Bensen WG; Bianchi F; Cividino A; Gordon M; Kaminska E; Scocchia T; Petrie A; Stephenson GF; Goldsmith CH
J Rheumatol; 1999 Jul; 26(7):1545-9. PubMed ID: 10405943
[TBL] [Abstract][Full Text] [Related]
9. [Morphologic study of iliac crest spongiosa in patients with osteoporosis treated according to the ADFR (activation, depression of resorption, formation, repeat the cycle) with parathyroid hormone and diphosphonates (Hannover PTH I study)].
Delling G; Dreyer T; Hahn M; Vogel M; Rittinghaus EF; Hesch RD
Z Orthop Ihre Grenzgeb; 1990; 128(1):1-5. PubMed ID: 2138378
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of osteoporosis using the ADFR schedule (especially with parathyroid hormone and etidronate)].
Ziegler R
Internist (Berl); 1991 Feb; 32(2):76-9. PubMed ID: 1903362
[No Abstract] [Full Text] [Related]
11. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
[TBL] [Abstract][Full Text] [Related]
12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
13. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
Greenspan SL; Holland S; Maitland-Ramsey L; Poku M; Freeman A; Yuan W; Kher U; Gertz B
Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
[TBL] [Abstract][Full Text] [Related]
14. Reduced parathyroid hormone response to peroral phosphate in osteoporotic patients.
Ittner J; Dambacher MA; Muff R; Rüegsegger P; Trechsel U; Fischer JA
Miner Electrolyte Metab; 1986; 12(3):199-203. PubMed ID: 3014300
[TBL] [Abstract][Full Text] [Related]
15. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.
Storm T; Steiniche T; Thamsborg G; Melsen F
J Bone Miner Res; 1993 Feb; 8(2):199-208. PubMed ID: 8442438
[TBL] [Abstract][Full Text] [Related]
16. Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study.
Hodsman AB
Bone Miner; 1989 Jan; 5(2):201-12. PubMed ID: 2493274
[TBL] [Abstract][Full Text] [Related]
17. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
Adachi JD; Roux C; Pitt PI; Cooper C; Moniz C; Dequeker J; Ioannidis G; Cawley MI; Jenkins EA; Walker-Bone KE; Pack S; Stephenson GF; Laan RF; Brown J; Geusens P
J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
[TBL] [Abstract][Full Text] [Related]
18. Cyclic oral phosphate and etidronate increase femoral and lumbar bone mineral density and reduce lumbar spine fracture rate over three years.
Silberstein EB; Schnur W
J Nucl Med; 1992 Jan; 33(1):1-5. PubMed ID: 1730972
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the effects of oestrogen/progestogen, high-dose oral calcium, intermittent cyclic etidronate and an ADFR regime on calcium kinetics and bone mass in postmenopausal women with spinal osteoporosis.
Hasling C; Charles P; Jensen FT; Mosekilde L
Osteoporos Int; 1994 Jul; 4(4):191-203. PubMed ID: 7949749
[TBL] [Abstract][Full Text] [Related]
20. The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women.
Evans RA; Somers NM; Dunstan CR; Royle H; Kos S
Osteoporos Int; 1993 Mar; 3(2):71-5. PubMed ID: 8453193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
